Gastroparesis Treatments In Wesley Chapel, FL

The 2025 AGA guideline recommends against the routine initial use of G-POEM or gastric electrical stimulation. Both are reserved for patients whose symptoms stay refractory after medical therapy has been optimized.

First-line looks like this: dietary changes toward small-particle, low-fat, low-residue meals, plus metoclopramide or erythromycin. Both drugs carry real limits. Metoclopramide has an FDA black box warning and can cause severe adverse effects that cap long-term use. Erythromycin loses effectiveness over time and brings its own side effects. The guideline also issued conditional recommendations against domperidone, prucalopride, aprepitant, nortriptyline, buspirone, and cannabidiol as first-line options.

The panel gave no recommendation at all on surgical pyloromyotomy or pyloroplasty. It named both as knowledge gaps. That is an honest statement about the state of the evidence, and it is worth knowing before anyone quotes you a success rate.

Dr. Grandhige’s stated position on his own procedures is consistent with that sequencing. He does not operate on patients unlikely to benefit, and he says the most important skill in foregut surgery is knowing when not to operate and which operation not to do. He is also direct about the cost of that policy: the patients he declines are often the least happy, because they arrive frustrated and want a definitive answer. His view is that they would be less happy still if an unnecessary operation left the symptoms exactly where they were.

Most patients are seen within two weeks, and always within four. From first consultation to procedure runs four to eight weeks, depending on whether your testing is already done.

If your testing is complete when you arrive, one consultation is usually all that is needed. The diagnosis can be confirmed at that visit, options discussed, and insurance authorization started immediately. The procedure can be scheduled as early as four weeks out.

If testing is not complete, the first visit covers records review, education, and test planning. Studies get ordered and coordinated. A second visit follows about four weeks later to review results and finalize the plan. That path puts the procedure at roughly eight weeks from the first visit. The two-visit structure is deliberate. It buys time for objective confirmation instead of a rushed decision.

Insurance authorization runs in parallel and is handled entirely by the office: gathering documentation, submitting testing results and clinical notes, and communicating directly with the insurer. It can take four to six weeks on more complex cases. Authorization is secured before anything is scheduled, so there are no denials or surprise bills after the fact.

You can shorten all of this yourself. Send your records to info@tampareflux.com ahead of your appointment: prior endoscopy and pathology reports, gastric emptying study results, any pH testing or manometry, barium swallow or other imaging, office notes from gastroenterology, ENT, pulmonology, allergy, and primary care, a current medication list, and a list of prior surgeries. Dr. Grandhige personally reviews all of it before you walk in, which turns the consultation into an explanation instead of a data-gathering session.

Signed record releases get sent the day you call, but records still arrive late or incomplete more often than not. Fax-based systems and incompatible electronic records remain the bottleneck. Patients who bring their own material get a more definitive answer at the first visit. The patient forms page has the intake paperwork.

Two things moved this year that affect how gastroparesis decisions get made.

The AGA guideline arrived in late 2025 with 12 conditional recommendations, and it is the first evidence-based guideline written specifically for this condition. It sharpened the testing standard and pushed procedures later in the sequence.

The second development is a drug. Naronapride, an investigational oral prokinetic, cleared Phase 2b. The MOVE-IT trial enrolled 328 adults with at least moderate idiopathic or diabetic gastroparesis in a 12-week, double-blind, placebo-controlled study. It met its primary endpoint on the ANMS GCSI-DD core symptom score at the 20 mg and 40 mg three-times-daily doses, with reported improvements across nausea, early satiety, post-prandial fullness, and upper abdominal pain. Results were announced in May 2026, and in June 2026 the sponsors said they are advancing into Phase 3 registration studies with a planned US new drug application.

What that means for your treatment options today: nothing. It is investigational. It is not approved, not prescribable, and not something you can request. It is relevant only to sequencing. If your oral options are limited and your symptoms are tolerable, a realistic pipeline timeline is one input into how quickly you move toward a procedure. The practice blog covers developments like this as they land.

If you have been told you have gastroparesis and never received a testing-based explanation of why, that is the gap to close first. The evaluation starts with confirming the diagnosis, excluding what else could be causing it, and telling you plainly which of your symptoms a procedure could reasonably improve.